Baylor College of Medicine

 

3rd Annual Hematologic Malignancies Symposium
A

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Outcomes, Enasidenib/Ivosidenib, HMA Combinations, Options for Clonal Escape

By 3rd Annual Hematologic Malignancies Symposium FEATURING Andrew Wei
By 3rd Annual Hematologic Malignancies Symposium FEATURING Andrew Wei
415 views
April 7, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
3rd Annual Hematologic Malignancies Symposium
26:33

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

3rd Annual Hematologic Malignancies Symposium

A. Perl

144 views
07:34

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

3rd Annual Hematologic Malignancies Symposium

A. Perl

214 views
15:35

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

3rd Annual Hematologic Malignancies Symposium

G. Roboz

126 views
22:10

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

3rd Annual Hematologic Malignancies Symposium

C. DiNardo

231 views
26:23

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR, In…

3rd Annual Hematologic Malignancies Symposium

H. Carraway

128 views
15:41

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Out…

3rd Annual Hematologic Malignancies Symposium

A. Wei

415 views